US2023142697A1PendingUtilityA1
Glycan-Interacting Compounds and Methods of Use
Est. expiryNov 17, 2036(~10.3 yrs left)· nominal 20-yr term from priority
C07K 2317/92C07K 2317/622C07K 2317/524C07K 16/30A61P 35/04C07K 2317/74C07K 2317/24C07K 2317/41C07K 16/46A61K 2039/505C07K 2317/31C07K 16/2809C07K 2317/565C07K 2317/73C07K 16/3076C07K 2317/72C07K 16/44
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure provides antibodies with T cell-interacting regions and/or glycan-interacting regions. Bispecific antibodies capable of recruiting T cells to cancer cells are also provided, including bispecific antibodies capable of recruiting T cells to cancer cells expressing sialyl Tn (STn). The present disclosure also includes methods for killing cells by targeting them with antibodies having T cell-interacting regions.
Claims
exact text as granted — not AI-modified1 . An antibody comprising:
a heavy chain variable domain (VH) comprising an amino acid sequence with at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 66, 64, 65, 67, and 68; and a light chain variable domain (VL) comprising an amino acid sequence with at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 71, 69, 70, and 72.
2 - 50 . (canceled)Join the waitlist — get patent alerts
Track US2023142697A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.